Understanding And Influencing Physical Activity To Improve Population Health
Funder
National Health and Medical Research Council
Funding Amount
$4,668,376.00
Summary
Three of Australia's leading researchers on physical activity and population health will use new NHMRC program grant funding to consolidate and extend their already internationally-recognised studies. Doing regular physical activity is very important for maintaining good health. It helps to prevent weight gain, type 2 diabetes, heart disease and breast and colon cancer. Unfortunately, most Australian adults are not active enough for health benefits. Rates of overweight and obesity are increasing ....Three of Australia's leading researchers on physical activity and population health will use new NHMRC program grant funding to consolidate and extend their already internationally-recognised studies. Doing regular physical activity is very important for maintaining good health. It helps to prevent weight gain, type 2 diabetes, heart disease and breast and colon cancer. Unfortunately, most Australian adults are not active enough for health benefits. Rates of overweight and obesity are increasing rapidly; more than 50% of Australian adults are above the healthy weight range. Rates of type 2 diabetes have doubled in the past 20 years. New ideas and practical tools are therefore needed to tackle these serious ‘diseases of inactivity’. To this end, Professors Neville Owen, Adrian Bauman and Wendy Brown will bring together innovative and practically useful scientific approaches drawn from psychology, epidemiology and exercise physiology. The approach is interdisciplinary – it combines theories and methods from their individual disciplines in an innovative manner, within a public health framework. Their research to date has developed better methods for measuring people’s exercise habits and has provided new insights into how personal, social and environmental circumstances can make people less active. They have also shown how to design and deliver wide-reaching programs for different social groups and evaluated their effectiveness. Their new research program will build on and significantly extend these ideas and approaches into new areas.For example, they will develop new measures of incidental physical activity and sedentary behaviour and will develop and test new, complex community interventions.Their new program will involve in-depth study of some of the most challenging researchproblems in an important and under-researched area of public health. They will further combine their disciplines and the skills of their research team in new, creative and practical ways, to answer important research questions about physical activity and population health. These ideas and approaches will be used to identify practical ways to help more people to be more physically active.Read moreRead less
Sitting Less And Moving More: Population Health Research To Understand And Influence Sedentary Behaviour
Funder
National Health and Medical Research Council
Funding Amount
$6,367,518.00
Summary
The majority of Australian adults spend most of their waking hours sitting: at home, at work, and in their cars; most do not participate in exercise or sport. This leads to weight gain and to diseases of inactivity (particularly diabetes, heart disease, cancer and depression). New research will measure sitting time and the physical activity in people's daily lives, what factors encourage inactivity, and how to increase activity levels, especially among the ageing 'baby boomer' population.
The goal of the proposed Program is to improve treatments forpain, especially persistent pain, which remains a poorly managed global health burden. Our pre-eminent team integrates a unique set of complementary research skills in using peptides derived from venomous invertebrates to dissect the pharmacology of pain pathways in persistent pain states, and develop these novel peptides to the point where they can be considered for pre-clinical development in collaboration with commercial partners.
A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on ....A major obstacle to the development of safer and more effective pain treatments is the poorly defined nature of the different pathways involved in chronic pain. The applicant team bring together a unique set of research expertise in using neurotoxins to define, at the molecular level, how the nervous system functions. The applicants also share a common interest in understanding and improving treatments for pain, especially chronic pain which continues to remain poorly managed Through a focus on pain research, the Program will significantly enhance the scope of existing multidisciplinary collaborations between the Cis Lewis Alewood, Adams and Christie, which have already made a considerable impact in the fields of pharmacology and neuroscience. The CIs also have considerable experience in the development of pain therapeutics, having discovered two conopeptides now under commercial development with AMRAD (AM336) and Xenome Ltd (Xen2174). This Program will discover and use highly selective conopeptides such as these to dissect the pharmacology of peripheral pain pathways and their projections into the central nervous system, and to identify and characterise new targets amenable to drug intervention. The long-term goal of the Program is to discover new targets in pain pathways and develop conopeptides that act on these targets in animal models of chronic pain. These molecules will be optimised within the Program to the point where they can be considered for pre-clinical development in collaboration with commercial partners.Read moreRead less
IMPROVING STROKE OUTCOMES: NEW TARGETS AND THERAPIES
Funder
National Health and Medical Research Council
Funding Amount
$7,212,064.00
Summary
Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using ....Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using the clot dissolving agent tPA to extend the time during which the drug may be effective beyond the three-hours currently used. In the next phase of our program we plan to expand the basic science component to identify parts of brain cells (axons and dendrites) which may yield important information about new drugs to protect the brain. We will use our novel summary data technique to test drugs in animal models more appropriate to the human stroke paradigm than have been used in the past In clinical studies we will follow our theme of identifying new targets for therapy using sophisticated PET and MRI imaging techniques, both in patients who are at great risk of stroke recurrence after a minor warning stroke and those with stroke caused by bleeding within the brain. These studies will provide information about predictors of recurrent and worsening stroke which may be modified by new therapies. The final stage in identifying new therapies is the Phase III clinical trial. We will complete one of these in which the most appropriate drug preventing further strokes in a major new stroke subtype will be identified. Toward the end of the program, we will commence phase 3 studies of drugs we have selected as being most likely to protect the brain based on our animal experiments. The main benefit of this unique collaborative research model is to efficiently identify new therapies to reduce the burden of stroke, currently the second most common cause of death globally.Read moreRead less
Development And Refinement Of Neural Connections In The Adult Brain In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$8,061,596.00
Summary
Our group will use innovative approaches such as advanced imaging and cell-sorting and development of animal models to determine how new neurons are generated, how they travel to different parts of the brain and how they integrate into the existing brain circuitry. These discoveries will point to new ways in which to treat brain damage both during ageing and during pathology. Since team members have previously been involved in progressing molecular discovery to clinical trials, we are also in a ....Our group will use innovative approaches such as advanced imaging and cell-sorting and development of animal models to determine how new neurons are generated, how they travel to different parts of the brain and how they integrate into the existing brain circuitry. These discoveries will point to new ways in which to treat brain damage both during ageing and during pathology. Since team members have previously been involved in progressing molecular discovery to clinical trials, we are also in a good position to exploit these discoveries in partnership with the biopharmaceutical industry.Read moreRead less